$14.25
+0.17
(+1.21%)▲
1.82%
Downside
Day's Volatility :2.85%
Upside
1.04%
30.35%
Downside
52 Weeks Volatility :49.85%
Upside
27.99%
Period | Embecta Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 0.78% | -2.1% | 0.0% |
6 Months | 40.39% | 4.9% | 0.0% |
1 Year | -12.09% | 16.0% | 0.0% |
3 Years | -52.47% | 9.2% | -26.4% |
Market Capitalization | 812.4M |
Book Value | -$13.24 |
Dividend Share | 0.6 |
Dividend Yield | 4.26% |
Earnings Per Share (EPS) | 1.2 |
PE Ratio | 11.73 |
Wall Street Target Price | 16.07 |
Profit Margin | 6.23% |
Operating Margin TTM | 29.98% |
Return On Assets TTM | 9.64% |
Return On Equity TTM | 0.0% |
Revenue TTM | 1.1B |
Revenue Per Share TTM | 19.44 |
Quarterly Revenue Growth YOY | -4.8% |
Gross Profit TTM | 774.9M |
EBITDA | 230.4M |
Diluted Eps TTM | 1.2 |
Quarterly Earnings Growth YOY | -0.04 |
EPS Estimate Current Year | 2.39 |
EPS Estimate Next Year | 2.27 |
EPS Estimate Current Quarter | 0.46 |
EPS Estimate Next Quarter | 0.53 |
What analysts predicted
Upside of 12.77%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | - |
Net Income | 432.0M | - |
Net Profit Margin | 38.95% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 2.12% |
Net Income | 427.6M | ↓ 1.02% |
Net Profit Margin | 39.39% | ↑ 0.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 7.32% |
Net Income | 414.8M | ↓ 2.99% |
Net Profit Margin | 35.61% | ↓ 3.78% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 3.05% |
Net Income | 223.6M | ↓ 46.09% |
Net Profit Margin | 19.8% | ↓ 15.81% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 0.77% |
Net Income | 70.4M | ↓ 68.52% |
Net Profit Margin | 6.28% | ↓ 13.52% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 0.0% |
Net Income | 70.4M | ↑ 0.0% |
Net Profit Margin | 6.28% | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 277.1M | ↑ 0.51% |
Net Income | 14.0M | ↓ 60.23% |
Net Profit Margin | 5.05% | ↓ 7.72% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 286.1M | ↑ 3.25% |
Net Income | 15.2M | ↑ 8.57% |
Net Profit Margin | 5.31% | ↑ 0.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 281.9M | ↓ 1.47% |
Net Income | 6.0M | ↓ 60.53% |
Net Profit Margin | 2.13% | ↓ 3.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 277.3M | ↓ 1.63% |
Net Income | 20.1M | ↑ 235.0% |
Net Profit Margin | 7.25% | ↑ 5.12% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 287.2M | ↑ 3.57% |
Net Income | 28.9M | ↑ 43.78% |
Net Profit Margin | 10.06% | ↑ 2.81% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 272.5M | ↓ 5.12% |
Net Income | 14.7M | ↓ 49.13% |
Net Profit Margin | 5.39% | ↓ 4.67% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 745.0M | - |
Total Liabilities | 126.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 738.0M | ↓ 0.94% |
Total Liabilities | 166.0M | ↑ 31.75% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 788.0M | ↑ 6.78% |
Total Liabilities | 194.0M | ↑ 16.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 37.87% |
Total Liabilities | 2.0B | ↑ 919.48% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 11.78% |
Total Liabilities | 2.0B | ↑ 2.95% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 0.0% |
Total Liabilities | 2.0B | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 1.09% |
Total Liabilities | 2.0B | ↓ 0.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 3.48% |
Total Liabilities | 2.1B | ↑ 1.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 3.01% |
Total Liabilities | 2.0B | ↓ 1.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 0.28% |
Total Liabilities | 2.0B | ↓ 1.22% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 1.49% |
Total Liabilities | 2.0B | ↓ 2.09% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 5.66% |
Total Liabilities | 2.0B | ↑ 3.15% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 505.0M | - |
Investing Cash Flow | -69.0M | - |
Financing Cash Flow | -436.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 498.5M | ↓ 1.29% |
Investing Cash Flow | -42.0M | ↓ 39.13% |
Financing Cash Flow | -456.6M | ↑ 4.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 456.0M | ↓ 8.53% |
Investing Cash Flow | -39.0M | ↓ 7.14% |
Financing Cash Flow | -417.0M | ↓ 8.67% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 412.2M | ↓ 9.61% |
Investing Cash Flow | -24.0M | ↓ 38.46% |
Financing Cash Flow | -48.0M | ↓ 88.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.0M | ↓ 121.52% |
Investing Cash Flow | -5.8M | ↑ 23.4% |
Financing Cash Flow | -20.7M | ↑ 239.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↓ 28.46% |
Investing Cash Flow | -6.8M | ↑ 17.24% |
Financing Cash Flow | -12.2M | ↓ 41.06% |
Sell
Neutral
Buy
Embecta Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Embecta Corp | 7.22% | 40.39% | -12.09% | -52.47% | -52.47% |
Intuitive Surgical, Inc. | 5.57% | 32.77% | 81.8% | 40.07% | 170.84% |
Resmed Inc. | 2.45% | 12.58% | 59.86% | -8.89% | 65.62% |
Becton, Dickinson And Company | -0.89% | 0.24% | -9.14% | -4.77% | -9.77% |
West Pharmaceutical Services Inc | 6.45% | -13.29% | -5.52% | -27.77% | 114.23% |
Alcon Ag | -6.44% | 15.36% | 23.47% | 6.36% | 55.58% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Embecta Corp | 11.73 | 11.73 | NA | 2.39 | 0.0 | 0.1 | 0.04 | -13.24 |
Intuitive Surgical, Inc. | 81.26 | 81.26 | 3.74 | 6.89 | 0.16 | 0.08 | NA | 43.75 |
Resmed Inc. | 32.16 | 32.16 | 1.84 | 7.71 | 0.24 | 0.13 | 0.01 | 35.39 |
Becton, Dickinson And Company | 47.14 | 47.14 | 1.08 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
West Pharmaceutical Services Inc | 45.69 | 45.69 | 5.94 | 6.55 | 0.18 | 0.1 | 0.0 | 37.96 |
Alcon Ag | 41.42 | 41.42 | 3.43 | 3.06 | 0.05 | 0.03 | 0.0 | 42.35 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Embecta Corp | Sell | $812.4M | -52.47% | 11.73 | 6.23% |
Intuitive Surgical, Inc. | Buy | $183.0B | 170.84% | 81.26 | 28.51% |
Resmed Inc. | Buy | $35.7B | 65.62% | 32.16 | 23.15% |
Becton, Dickinson And Company | Buy | $68.0B | -9.77% | 47.14 | 7.13% |
West Pharmaceutical Services Inc | Buy | $22.3B | 114.23% | 45.69 | 17.37% |
Alcon Ag | Buy | $45.4B | 55.58% | 41.42 | 11.44% |
Insights on Embecta Corp
Revenue is down for the last 2 quarters, 287.2M → 272.5M (in $), with an average decrease of 5.1% per quarter
Netprofit is down for the last 2 quarters, 28.9M → 14.7M (in $), with an average decrease of 49.1% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 81.8% return, outperforming this stock by 93.9%
BlackRock Inc
Vanguard Group Inc
River Road Asset Management, LLC
Millennium Management LLC
American Century Companies Inc
Yacktman Asset Management Co
Organization | Embecta Corp |
Employees | 2200 |
CEO | Mr. Devdatt Kurdikar |
Industry | Healthcare |
Prelude Therapeutics Inc
$14.25
+1.21%
Collegium Pharmaceutical Inc
$14.25
+1.21%
Xoma Royalty Corp
$14.25
+1.21%
Gossamer Bio Inc
$14.25
+1.21%
Patterson Companies, Inc.
$14.25
+1.21%
Dynavax Technologies Corporation
$14.25
+1.21%
Mesoblast
$14.25
+1.21%
Sight Sciences Inc
$14.25
+1.21%
Voyager Therapeutics, Inc.
$14.25
+1.21%